Human Serum Albumin-Platinum(II) Agent Nanoparticles Inhibit Tumor Growth Through Multimodal Action Against the Tumor Microenvironment
Authors:
- 28 November 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (1) , 346-357
Abstract
To overcome the limitations of traditional platinum (Pt)-based drugs and further improve the targeting ability and therapeutic efficacy in vivo, we proposed to design a human serum albumin (HSA)-Pt agent complex nanoparticle (NP) for cancer treatment by multimodal action against the tumor microenvironment. We not only synthesized a series of Pt(II) di-2-pyridone thiosemicarbazone compounds and obtained a Pt(II) agent [Pt(Dp44mT)Cl] with significant anticancer activity but also successfully constructed a novel HSA-Pt(Dp44mT) complex nanoparticle delivery system. The structure of the HSA-Pt(Dp44mT) complex revealed that Pt(Dp44mT)Cl binds to the IIA subdomain of HSA and coordinates with His-242. The HSA-His242-Pt-Dp44mT NPs had an obvious effect on the inhibition of tumor growth, which was superior to that of Dp44mT and Pt(Dp44mT)Cl, and they had almost no toxicity. In addition, the HSA-His242-Pt-Dp44mT NPs were found to kill cancer cells by inducing apoptosis, autophagy, and inhibiting angiogenesis.Keywords
Funding Information
- Natural Science Foundation of Guangxi Zhuang Autonomous Region (2022GXNSFBA035491, 2022GXNSFGA035003)
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Education (CMEMR2021-A01)
- National Natural Science Foundation of China (22077021)
This publication has 59 references indexed in Scilit:
- Targeting and delivery of platinum-based anticancer drugsChemical Society Reviews, 2012
- Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in VivoJournal of Medicinal Chemistry, 2012
- Methemoglobin Formation by Triapine, Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and Other Anticancer Thiosemicarbazones: Identification of Novel Thiosemicarbazones and Therapeutics That Prevent This EffectMolecular Pharmacology, 2012
- Human serum albumin: From bench to bedsideMolecular Aspects of Medicine, 2012
- Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in LysosomesCancer Research, 2011
- Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor ActivityJournal of Medicinal Chemistry, 2010
- Thiosemicarbazones: The New Wave in Cancer TreatmentFuture Medicinal Chemistry, 2009
- Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase InhibitorsJournal of Medicinal Chemistry, 2009
- Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)Investigational New Drugs, 2007
- Structure, Recognition, and Processing of Cisplatin−DNA AdductsChemical Reviews, 1999